LBBAP vs. CS Pacing for CRT in Permanent Atrial Fibrillation and Heart Failure (SYNC-AF) (SYNC-AF)
Left Bundle Branch Area Pacing Versus Coronary Sinus Pacing for Cardiac Resynchronization Therapy for Patients With Permanent Atrial Fibrillation and Heart Failure: The SYNC-AF Trial
This is a prospective, multicenter, randomized controlled trial comparing Left Bundle Branch Area Pacing (LBBAP)-based cardiac resynchronization therapy (CRT) with conventional coronary sinus (CS) lead-based CRT in patients with permanent atrial fibrillation (AF) and heart failure (HF) who meet indications for CRT device implantation.
Atrial fibrillation and heart failure frequently coexist, and both rapid heart rate and its irregularity contribute to worsening cardiac function. Atrioventricular junction (AVJ) ablation combined with CRT (biventricular pacing) has been established as an effective strategy for rate control and cardiac resynchronization in this population, supported by Class I recommendation in the 2021 ESC guidelines. However, conventional biventricular CRT via the CS lead can induce artificial electrical dyssynchrony, particularly in patients with a narrow QRS complex, potentially limiting its benefit.
Conduction system pacing (CSP), including LBBAP, has emerged as a physiologic alternative that directly stimulates the native conduction system, preserving synchronous ventricular activation. Recent evidence (ALTERNATIVE-AF trial) suggests CSP may be superior to biventricular CRT in permanent AF patients undergoing AVJ ablation. However, no randomized controlled trial has directly compared LBBAP-based CRT with CS lead-based CRT in this specific population.
The SYNC-AF trial will randomize 44 patients (22 per arm) to either LBBAP or CS pacing for CRT. The primary endpoint is change in left ventricular ejection fraction (LVEF) at 12 months as assessed by echocardiography in a blinded core laboratory. Secondary endpoints include changes in QRS duration, major adverse clinical events, device/procedure-related complications, and ventricular arrhythmia burden.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
ECHOCARDIOGRAPHIC CORE LAB:
All echocardiographic assessments (LVEF, LVESV, LVEDV, etc.) are performed and interpreted by a blinded independent core laboratory at Severance Hospital to ensure objective and consistent measurement.
FOLLOW-UP SCHEDULE:
Screening (implant day) → Visit 1 (2 weeks-1 month) → Visit 2 (3 months ±3 months) → Visit 3 (6 months ±3 months) → Visit 4 (12 months ±3 months).
STATISTICAL ANALYSIS:
Primary analysis follows the Intention-To-Treat (ITT) principle. Per-Protocol (PP) analysis will be performed as sensitivity analysis. The primary endpoint (LVEF change at 12 months) will be compared using Student's t-test or Wilcoxon rank-sum test. Time-to-event analyses will use Kaplan-Meier survival curves with log-rank test and Cox proportional hazards model.
SAMPLE SIZE:
44 patients total (22 per arm). Based on the assumption of an absolute 10% greater improvement in LVEF with LBBAP-CRT vs. BiV-CRT, with 80% power and 5% two-sided alpha, with 10% dropout allowance.
PARTICIPATING CENTERS:
Multiple centers in the Republic of Korea (at least 4 centers), led by Severance Hospital, Yonsei University College of Medicine.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Tae-Hoon Kim, Professor
- Telefonnummer: +82-2-2228-8467
- E-post: thkimcardio@yuhs.ac
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Age ≥19 years
- Indication for CRT (CRT-P or CRT-D) device implantation per current guidelines
- Permanent atrial fibrillation (with or without planned AVJ ablation)
- Ability to understand the purpose of the study and provide written informed consent
Exclusion Criteria:
- Prosthetic tricuspid valve
- Prior myocardial infarction involving the interventricular septal area
- Life expectancy less than 12 months
- Unable to comply with planned 12-month follow-up for any reason
- Pregnancy
- History of heart transplantation
- Persistent left superior vena cava (PLSVC)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: LBBAP Group
Participants undergo CRT device implantation (CRT-P or CRT-D) with Left Bundle Branch Area Pacing (LBBAP) as the left ventricular lead strategy.
LBBAP is attempted first; if not feasible, crossover to CS lead is permitted.
AVJ ablation is performed per clinical indication.
|
CRT device (CRT-P or CRT-D) implantation using LBBAP as the left ventricular pacing lead.
A pacing lead is advanced through the interventricular septum to achieve left bundle branch area capture, confirmed by pacing parameters and electrocardiographic criteria (RBBB-like pattern with short R-peak latency in V5/V6).
RV lead is implanted in standard fashion.
AVJ ablation may be performed per clinical indication.
|
|
Aktiv komparator: CS Pacing Group
Participants undergo CRT device implantation (CRT-P or CRT-D) with conventional Coronary Sinus (CS) lead-based pacing as the left ventricular lead strategy.
AVJ ablation is performed per clinical indication.
|
CRT device (CRT-P or CRT-D) implantation using a conventional coronary sinus (CS) lead as the left ventricular pacing lead.
The CS lead is advanced via the coronary sinus into a lateral or posterolateral cardiac vein to achieve biventricular pacing.
RV lead is implanted in standard fashion.
AVJ ablation may be performed per clinical indication.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline Left Ventricular Ejection Fraction (LVEF) at 12 Months
Tidsramme: Baseline (at the time of device implantation) and 12 months post-implantation
|
Change in left ventricular ejection fraction (LVEF) from baseline to 12 months post-implantation, as measured by transthoracic echocardiography performed and interpreted by a blinded independent central core laboratory.
LVEF is assessed using the biplane Simpson method.
|
Baseline (at the time of device implantation) and 12 months post-implantation
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of patients with absolute LVEF increase ≥5% at 12 months
Tidsramme: 12 months post-implantation
|
Echocardiographic CRT response defined as absolute improvement in LVEF of ≥5% or ≥10% from baseline at 12 months, assessed by blinded core lab.
|
12 months post-implantation
|
|
Proportion of patients with absolute LVEF increase ≥10% at 12 months
Tidsramme: 12 months post-implantation
|
Echocardiographic CRT response defined as absolute improvement in LVEF of ≥5% or ≥10% from baseline at 12 months, assessed by blinded core lab.
|
12 months post-implantation
|
|
Change in QRS Duration From Baseline
Tidsramme: Immediately post-implant and at 12 months
|
QRS duration measured from surface ECG in milliseconds.
|
Immediately post-implant and at 12 months
|
|
Time to First Treated Ventricular Arrhythmia
Tidsramme: Up to 12 months
|
Time from randomization to first detection of treated ventricular arrhythmia (VT/VF) recorded by the implanted device within 12 months.
|
Up to 12 months
|
|
Composite of All-Cause Death and Heart Failure Hospitalization
Tidsramme: Up to 12 months (first occurrence)
|
Clinical events adjudicated by an independent committee.
Heart failure hospitalization defined as unplanned outpatient/ED visit or inpatient admission with HF signs/symptoms requiring intravenous therapy.
|
Up to 12 months (first occurrence)
|
|
All-cause mortality
Tidsramme: Up to 12 months (first occurrence)
|
Clinical events adjudicated by an independent committee.
Heart failure hospitalization defined as unplanned outpatient/ED visit or inpatient admission with HF signs/symptoms requiring intravenous therapy.
|
Up to 12 months (first occurrence)
|
|
Heart failure hospitalization
Tidsramme: Up to 12 months (first occurrence)
|
Clinical events adjudicated by an independent committee.
Heart failure hospitalization defined as unplanned outpatient/ED visit or inpatient admission with HF signs/symptoms requiring intravenous therapy.
|
Up to 12 months (first occurrence)
|
|
Cardiovascular death
Tidsramme: Up to 12 months (first occurrence)
|
Clinical events adjudicated by an independent committee.
Heart failure hospitalization defined as unplanned outpatient/ED visit or inpatient admission with HF signs/symptoms requiring intravenous therapy.
|
Up to 12 months (first occurrence)
|
|
Immediate procedural success rate of LBBAP lead implantation
Tidsramme: Immediately after the implantation procedure
|
Successful LBBAP lead placement defined by achievement of left bundle branch capture with acceptable pacing threshold (≤1.5V/0.5ms),
impedance (300-1200Ω), and electrocardiographic criteria (RBBB pattern, short R-peak latency in V5/V6).
|
Immediately after the implantation procedure
|
|
Lead capture loss rate at 12 months
Tidsramme: 12 months post-implantation
|
Loss of left bundle branch capture or inability to maintain pacing threshold <2.5V/0.5ms
at 12 months.
|
12 months post-implantation
|
|
Composite Rate of Worsening Heart Failure by Echocardiographic Criteria
Tidsramme: Up to 12 months
|
Composite endpoint defined as ≥5% absolute decrease in LVEF from baseline or ≥15% increase in LVESV from baseline during follow-up.
|
Up to 12 months
|
|
Device and Procedure-Related Complications
Tidsramme: Up to 12 months (device/procedure-related complications within 7 days for acute; up to 12 months for chronic)
|
All device/procedure-related complications and reinterventions occurring up to 12 months, adjudicated by an independent events committee.
|
Up to 12 months (device/procedure-related complications within 7 days for acute; up to 12 months for chronic)
|
|
Reintervention Rate
Tidsramme: Up to 12 months
|
All device/procedure-related complications and reinterventions occurring up to 12 months, adjudicated by an independent events committee.
|
Up to 12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 4-2025-1786
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .